Differentiating TYK2 inhibitors with real-world evidence in psoriasis

For a competitive drug launch, the difference between share gained and share lost often comes down to how well the brand team understands the market before day one. This case study shows how a leading pharmaceutical manufacturer used real-world evidence to sharpen launch strategy for an oral TYK2 inhibitor in psoriasis, uncovering targeting opportunities that fragmented data would have missed.

What you'll learn:

• Why the growth pathway apremilast used to expand the psoriasis market points to a similar opportunity for oral TYK2 inhibitors, and how to identify the topical-to-systemic patients most ready to advance
  
  
• How linking patients to prescribers across a longitudinal cohort revealed NPs and PAs as high-value targets in community dermatology, reshaping the field force targeting plan
  
  
• How real-world insights on free drug program dynamics, treatment discontinuation and prescriber behavior can inform differentiated positioning before launch, when the decisions that define share are still on the table